-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Assembly Biosciences, Lowers Price Target to $48

Benzinga·11/03/2026 16:17:08
Diffusion vocale
UBS analyst Ashwani Verma maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and lowers the price target from $52 to $48.